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Abstract The Reproducibility Project: Cancer Biology seeks to address growing concerns about
the reproducibility in scientific research by conducting replications of selected experiments from a
number of high-profile papers in the field of cancer biology. The papers, which were published
between 2010 and 2012, were selected on the basis of citations and Altmetric scores
(Errington et al., 2014). This Registered Report describes the proposed replication plan of key
experiments from “Systematic identification of genomic markers of drug sensitivity in cancer cells”
by Garnett and colleagues, published in Nature in 2012 (Garnett et al., 2012). The experiments to
be replicated are those reported in Figures 4C, 4E, 4F, and Supplemental Figures 16 and 20.
Garnett and colleagues performed a high throughput screen assessing the effect of 130 drugs on
639 cancer-derived cell lines in order to identify novel interactions for possible therapeutic
approaches. They then tested this approach by exploring in more detail a novel interaction they
identified in which Ewing’s sarcoma cell lines showed an increased sensitivity to PARP inhibitors
(Figure 4C). Mesenchymal progenitor cells (MPCs) transformed with the signature EWS-FLI1
translocation, the hallmark of Ewing’s sarcoma family tumors, exhibited increased sensitivity to the
PARP inhibitor olaparib as compared to MPCs transformed with a different translocation (Figure
4E). Knockdown mediated by siRNA of EWS-FLI1 abrogated this sensitivity to olaparib (Figure 4F).
The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science
and Science Exchange, and the results of the replications will be published by eLife.
DOI: 10.7554/eLife.13620.001
Introduction
In their 2012Nature paper, Garnett and colleagues implemented a large-scale high throughput in vitro
screen designed to assess interactions between drugs and cancer-derived human cell lines
(Garnett et al., 2012). This study leveraged a collection of over 600 cell lines screened across 130
drugs, with the aim to uncover new interactions between known cancers and known drugs in order to
identify new potential therapeutic avenues using extant drugs. They captured a large number of
known gene-drug interactions of clinically active drugs and identified several novel gene–drug associa-
tions. The ability to accurately capture a large number of known clinically relevant drug response bio-
markers as well as preferential cancer type sensitivities known to occur in the clinic, such as decreased
sensitivity to BRAF inhibitors in BRAF mutant colorectal cancers relative to melanomas, demonstrated
the effectiveness of this large-scale pharmacogenomic approach. A similar approach of interrogating
a large panel of human cancer cell lines of diverse lineages to predict drug sensitivity was conducted
and reported by Barretina and colleagues at the same time (Barretina et al., 2012).
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Garnett and colleagues identified an unexpected highly significant association between the EWS-
FLI1 translocation and sensitivity to the PARP inhibitor olaparib (Garnett et al., 2012). The EWS-FLI1
translocation is a defining cytogenetic characteristic of Ewing’s sarcoma family tumors (ESFTs). ESFTs
are highly malignant tumors that occur in the bone and soft tissue, usually in children. The transloca-
tion event combines part of the EWS protein to a member of the ETS transcription factor family; in
90% of cases, this is FLI1. This creates a novel transcription factor, EWS-FLI1, whose oncogenic actions
and mechanisms are still being fully explored. The translocation event is thought to be the initiating
event for the development of ESFTs (Erkizan et al., 2010; Lessnick and Ladanyi, 2012).
PARP1 has diverse functions in chromatin modification, mitosis and cell death, but it is most well
studied in the context of DNA repair and transcriptional regulation (Sonnenblick et al., 2014).
PARP1 is a key component of single stranded break (SSB) repair; however, loss of PARP1 activity can
be compensated for through DNA repair via homologous recombination (HR). This makes PARP1 an
interesting therapeutic target in the context of malignancies with deficient HR, such as BRCA1 and
BRCA2 mutant breast and ovarian cancers. In these cancers, loss of PARP activity results in synthetic
lethality; with both SSB and HR impaired, the accumulation of DNA damage eventually kills the
tumor cells (Jiang et al., 2015; Lord et al., 2015; Sonnenblick et al., 2014). PARP inhibitors
(PARPi), such as olaparib, are now at the forefront of treatment for breast and ovarian cancers, as
well as other malignancies (Feng et al., 2015).
In Figure 4C, a predicted interaction between Ewing’s sarcoma cells and the PARP inhibitor ola-
parib was tested. PARP inhibitors target BRCA-deficient cells that rely on alternative DNA damage
repair pathways involving PARP. A panel of cell lines representing Ewing’s sarcoma, a BRCA-defi-
cient line, as well as other osteosarcomas and cancers of soft tissue and epithelium were treated
with a range of concentrations of olaparib. The concentration of olaparib required to reduce colony
formation by 90% or more was much less for Ewing’s sarcoma cells (on par with the concentration
required for the BRCA-deficient cell line) than for the non-Ewing’s sarcoma cell lines. This experi-
ment will be replicated in Protocol 1.
In Figure 4E, the hypothesis that mouse mesenchymal progenitor cells (MPCs) that had been trans-
formed with the EWS-FLI1 translocation would confer sensitivity to olaparib was tested. The sensitivity
of these cells to olaparib were compared to MPCs transformed with a related translocation (FUS-
CHOP) as well as to SK-N-MC cells, which have the EWS-FLI1 translocation endogenously. Treatment
with olaparib did not inhibit the viability of the FUS-CHOP transformed MPCs, but did inhibit
the viability of the SK-N-MC cells. Olaparib also inhibited the viability of the EWS-FLI1 transformed
MEFs compared to the FUS-CHOP translocation. This experiment will be replicated in Protocol 2.
In Figure 4F, the effects of EWS-FLI1 depletion on a cell line carrying the translocation endoge-
nously was tested. A673 cells were transfected with siRNAs targeting EWS-FLI1, which resulted in a
partial rescue of sensitivity to olaparib compared to control siRNA transfected cells. This experiment
will be replicated in Protocol 3.
A paper published at the same time as Garnett and colleagues’ work also confirmed that Ewing’s
sarcoma cell lines were sensitive to treatment with PARP inhibitors (Brenner et al., 2012). In a previ-
ous paper, Brenner and colleagues reported that in prostate cancer PARP was a cofactor for wild-
type ETS transcription factors, which makes up one half of the defining translocation-based fusion
transcription factor of Ewing’s sarcoma, and that PARPi treatment of ETS positive prostate cancers
disrupted their growth (Brenner et al., 2011; Legrand et al., 2013). Based on this finding, they
examined the role of PARP1 and PARPi in Ewing’s sarcoma. Using immunoprecipitation, they
detected a direct interaction between the EWS-FLI1 fusion transcription factor and PARP1
(Brenner et al., 2012). Further, they reported that transforming a cell line (in this case, PC3 cells)
with the EWS-FLI1 translocation conferred sensitivity to treatment with olaparib, and that siRNA
mediated knockdown of EWS-FLI1 inhibited transwell migration of ESFT derived cell lines, but not
osteosarcoma cell lines (Brenner et al., 2012). Multiple groups have also reported the unique sensi-
tivity of EWS-FLI1 carrying Ewing’s sarcoma derived cell lines to olaparib (Lee et al., 2013;
Norris et al., 2014; Ordo´n˜ez et al., 2015). Additional work then demonstrated that, similar to
breast and ovarian cancers harboring BRCA1/2 mutations, Ewing’s sarcomas may also have defects
in DNA repair mechanisms, rendering them sensitive to PARP inhibition (Stewart et al., 2014). This
has led to the start of clinical trials treating Ewing’s sarcoma patients with combination therapies tar-
geting multiple DNA damage pathways and PARP inhibition. Results from a small scale nonrandom-
ized phase II human trial failed to show clinical efficacy in patients with metastatic and/or recurrent
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Ewing sarcoma treated with only olaparib (Choy et al., 2014), but other trials are underway to
explore the efficacy of PARP inhibition in combination with chemotherapy.
Materials and methods
Unless otherwise noted, all protocol information and references were derived from the original
paper or information obtained directly from the authors.
Protocol 1: Colony formation assay of Ewing’s sarcoma cell lines with
olaparib
This experiment assesses the sensitivity of Ewing’s sarcoma cell lines to the PARP inhibitor olaparib.
A colony formation assay will be performed with Ewing’s sarcoma, osteosarcoma, and BRCA2-defi-
cient and BRCA-proficient cells treated with a range of olaparib concentrations to determine the
effective concentration (number of colonies reduced by at least 90%). This protocol replicates the
experiment reported in Figure 4C and Supplemental Figure 16.
Sampling
. The experiment will be performed with two replicates and each experiment will use 5 Ewing’s
sarcoma cell lines and 7 osteosarcoma cell lines for a power of 82%.
 See Power calculations for details.
. The experiment will use the following cell lines:
 Ewing’s sarcoma cell lines:
& A673
& TC-71
& SK-N-MC
& CHLA-9
& CHLA-10
 Osteosarcoma cell lines:
& U-2-OS
& SJSA-1
& SAOS-2
& HOS
& MG-63
& 143B
& G-292
 BRCA2-deficient cell line: [positive control]
& DoTc2-4510
 BRCA-proficient cell line: [negative control]
& MES-SA
. Each cell line will be treated with the following conditions:
 Vehicle (DMSO)
 0.1 mM olaparib
 0.32 mM olaparib
 1 mM olaparib
 3.2 mM olaparib
 10 mM olaparib
Materials and reagents
Reagent Type Manufacturer Catalog # Comments
Olaparib Inhibitor Selleck Chemicals S1060 Source shared during communication with authors.
DMSO Chemical Sigma Aldrich 472301 Source shared during communication with authors.
Phosphate buffered saline (PBS) Buffer Gibco-Life Technologies 10010-023 Source shared during communication with authors.
Giemsa stain Chemical Sigma Aldrich G5637 Source shared during communication with authors.
Methanol Chemical Fisher Scientific BP1105-4 Source shared during communication with authors.
Continued on next page
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Continued
Reagent Type Manufacturer Catalog # Comments
DoTc2-4510 cells Cell line ATCC CRL-7920 Original source not specified.
MES-SA cells Cell line ATCC CRL-1976 Original source not specified
U-2-OS cells Cell line ATCC HTB-96 Original source not specified.
SAOS-2 cells Cell line ATCC HTB-85 Original source not specified.
SJSA-1 cells Cell line ATCC CRL-2098 Original source not specified.
HOS cells Cell line ATCC CRL-1543 Original source not specified.
MG-63 cells Cell line ATCC CRL-1427 Original source not specified.
143B cells Cell line ATCC CRL-8303 Replaces osteosarcoma cells used originally;
see Known Differences.
G-292 cells, clone A141B1 Cell line ATCC CRL-1423
A673 cells Cell line ATCC CRL-1598 Replaces the ES cells used originally;
see Known Differences
SK-N-MC cells Cell line ATCC HTB-10
TC-71 cells2 Cell line Children’s Oncology Group Cell
Culture and Xenograft Repository
CHLA-10 cells1 Cell line Children’s Oncology Group Cell
Culture and Xenograft Repository
CHLA-9 cells3 Cell line Children’s Oncology Group Cell
Culture and Xenograft Repository
Iscove’s modified DMEM (IMDM) Cell culture Life Technologies 12440-053 Not originally included.
L-glutamine Cell culture Life Technologies 25030-081 Not originally included.
Insulin-Transferrin-Selenium (ITS) Growth factor Lonza 17-838Z Not originally included.
McCoy’s 5A Medium Modified Cell culture ATCC 30-2007 Not originally included.
Fetal bovine serum (FBS) Cell culture Valley Biomedical BS3032 Original source not specified.
RPMI 1640 medium Cell culture ATCC 30-2001 Original source not specified.
Eagle’s Minimum Essential
Media (EMEM)
Cell culture ATCC 30-2003 Originally not specified.
5-bromo-2’-deoxyuridine Nucleoside Sigma B5002 Not originally included.
MEM Eagle with Earle’s BSS Cell culture Lonza 12-125F Not originally included.
DMEM – High Glucose Cell culture GE-Healthcare E15-883 Shared during communication with authors.
DMEM/F12 Cell culture Life Technologies 11320-033 Original source not specified.
1 See http://www.cogcell.org/dl/EFT_Lines_DataSheets/CHLA-10_Cell_Line_Data_Sheet_COGcell_org.pdf
2 See http://www.cogcell.org/dl/EFT_Lines_DataSheets/TC- 71_Cell_Line_Data_Sheet_COGcell_org.pdf
3 See http://www.cogcell.org/dl/EFT_Lines_DataSheets/CHLA- 9_Cell_Line_Data_Sheet_COGcell_org.pdf
Procedure
Notes:
. All cell lines will be sent for STR profiling and mycoplasma testing.
. A673 cells are maintained in DMEM with 10% FBS.
. SAOS-2 are maintained in McCoy’s 5A Medium Modified supplemented with 15% FBS.
. CHLA-10 cells and TC-71 are maintained in IMDM supplemented with 20% FBS, 4 mM L-gluta-
mine, 5 mg/ml insulin, 5 mg/ml transferrin and 5 ng/ml selenium
. DoTc2-4510 cells are maintained in DMEM/F12 with 5% FBS.
. U-2-OS cells, HOS cells and G-292 cells are maintained in McCoy’s 5A Medium Modified sup-
plemented with 10% FBS.
. MG-63 cells are maintained in EMEM supplemented with 10% FBS.
. 143B cells are maintained in Minimum essential medium (Eagle) in Earle’s BSS with 0.015 mg/
ml 5-bromo-2’-deoxyuridine, 90%; FBS, 10%.
. SJSA-1 cells and SK-N-MC cells are maintained in RPMI 1640 medium supplemented with 10%
FBS.
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. MES-SA cells are maintained in McCoy’s 5A Medium Modified supplemented with 10% FBS.
. All cells kept at 37˚C and 5% CO2.
. Olaparib is stored as a 10 mM stock in DMSO at -80˚C. Each aliquot is subjected to no more
than 5 freeze-thaw cycles.
1. Plate cells at low density in 6 well culture plates.
a. Seed 2,000 cells per well in 2 ml of appropriate medium.
b. Plate 6 wells per cell line in duplicate plates.
i. Each cell line undergoes 6 treatments (see Sampling section above).
ii. Label one plate A and one plate B for each cell line.
c. Let cells adhere overnight.
2. The following day treat cells with varying concentrations of drug:
a. Vehicle (DMSO at 0.1% v/v)
b. 0.1 mM olaparib
c. 0.32 mM olaparib
d. 1 mM olaparib
e. 2 mM olaparib
f. 10 mM olaparib
3. Replace media and drug every 3-4 days.
4. After 7 to 21 days, when sufficient colonies are visible in the DMSO controls, fix cells for
quantification.
a. Stain cells once sufficient numbers of colonies are visible in DMSO wells.
i. Sufficient colonies means at least 100 colonies, ideally over 200 colonies, are present
in the vehicle treated wells for each cell line.
ii. DoTc2-24510 cells were cultured for about 12 days in the original study.
b. Wash cells once in PBS.
c. Fix in ice-cold methanol for 30 min while gently shaking at room temperature.
d. Remove methanol and add Giemsa stain at 1:20 dilution in deionized water. Incubate for
4 hr at room temperature shaking or overnight at 4˚ shaking.
e. 4 hr later, or the following day, rinse cells with water and air dry.
5. Take brightfield images of plates and manually quantify the number of colonies, blinded, in
each well from each plate.
6. Determine and record the concentration at which colony formation was reduced by >90%
compared to DMSO controls for each plate.
Deliverables
. Data to be collected:
 Images of all plates
 Colony counts of each well
 Graph of each cell line and the concentration of olaparib required to reduce colony forma-
tion by >90% compared to DMSO controls. (Compare to Figure 4C)
Confirmatory analysis plan
. Statistical Analysis of the Replication Data:
 Wilcoxon-Mann-Whitney test for ordinal data of the effective concentration of olaparib to
reduce the colonies by at least 90% in Ewing’s sarcoma compared to osteosarcoma cell
lines. Perform for each group (A or B) of replicate plates.
. Meta-analysis of original and replication attempt effect sizes:
 This replication attempt will perform the statistical analysis listed above, compute the
effect sizes (for each independent attempt), compare them against the reported effect
size in the original paper and use a meta-analytic approach to combine the original and
replication effects, which will be presented as a forest plot.
Known differences from the original study
. The replication attempt will only examine Ewing’s sarcoma and osteosarcoma derived cell
lines, with the BRCA2-deficient cell line as a positive control, and will not include the remaining
cell types (soft tissue and epithelial).
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. Due to the inability to obtain any of the Ewing’s sarcoma cell lines used originally, and in con-
sultation with the original authors, the replication attempt will use A673, TC-71, CHLA-9, SK-
N-MC and CHLA-10 cells. The cell lines all carry the critical EWS/FLI1 translocation. The cells
used in the original study were ES1, ES6, ES7, ES8, and MHH-ES-1.
. Similarly, the replication attempt will use U-2-OS, SJSA-1, SAOS-2, HOS, MG-63, 143B, and G-
292 cells. 143B and G-292 cells were not used in the original study and CAL-72, HuO-3N1,
and NY cells that were used in the original study will not be included in this replication
attempt.
. All known differences are listed in the materials and reagents section above with the originally
used item listed in the comments section. All differences have the same capabilities as the
original and are not expected to alter the experimental design.
Provisions for quality control
The cell lines used in this experiment will undergo STR profiling to confirm identity and will be sent
for mycoplasma testing to ensure there is no contamination. The DMSO concentration, although not
originally reported, will be kept at a low percentage to avoid toxicity. All data obtained from the
experiment will be made publicly available, either in the published manuscript or as an open access
dataset available on the OSF (https://osf.io/nbryi/).
Protocol 2: Olaparib sensitivity in cells transformed with the EWS-FLI1
rearrangement
This experiment assesses if sensitivity to PARP inhibitors is due to the presence of the EWS-FLI1 rear-
rangement. Mouse mesenchymal progenitor cells (MPCs) transformed with EWS-FLI1, or the related
liposarcoma-associated translocation FUS-CHOP, will be analyzed for cellular viability after olaparib
treatment. This protocol replicates the experiment reported in Figure 4E.
Sampling
. The experiment will be repeated three times for a power of 99%.
 See Power calculations for details.
. The experiment will use three cell lines:
 EWS-FLI1 transformed MPCs
 FUS-CHOP transformed MPCs
 SK-N-MC cells
& These cells harbor the endogenous EWS-FUS1 translocation
. Each cell line will be treated with the following conditions in technical triplicate:
 No treatment [additional]
 Vehicle (DMSO)
 0.39 mM olaparib
 0.78 mM olaparib
 1.56 mM olaparib
 3.13 mM olaparib
 6.25 mM olaparib
 12.5 mM olaparib
Materials and reagents
Reagent Type Manufacturer Catalog # Comments
EWS-FLI1 transformed mouse
mesenchymal progenitor cells (MPCs)
Cell line Authors N/A Provided by the Stamenkovic lab
FUS-CHOP transformed mouse
mesenchymal progenitor cells (MPCs)
Cell line Authors N/A Provided by the Stamenkovic lab
SK-N-MC cells Cell line ATCC HTB-10 Source shared during
communication with authors.
Olaparib Inhibitor Selleck Chemicals S1060 Source shared during
communication with authors.
Continued on next page
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Continued
Reagent Type Manufacturer Catalog # Comments
DMSO Chemical Sigma D8418 Source shared during
communication with authors.
4% formaldehyde Chemical USB 19943 Source shared during
communication with authors.
Syto60 fluorescent nucleic acid stain Chemical Invitrogen S11342 Catalog # shared during
communication with authors.
FBS Cell culture Valley Biomedical BS3032 Original source not specified.
RPMI 1640 medium Cell culture ATCC 30-2001 Original source not specified.
Fluorescent plate reader Equipment LiCor Source shared during
communication with authors.
DMEM, low glucose,
GlutaMAX supplement, pyruvate
Cell culture Gibco 21885-025 Shared during
communication with authors.
MCDB 201 medium, with trace elements,
L-glutamine and 30 mM HEPES; powder
Cell culture Sigma M6770 Shared during
communication with authors.
Ascorbic acid-2-phosphate Cell culture Sigma A8960 Shared during
communication with authors.
Dexamethasone Chemical Sigma D8893 Shared during
communication with authors.
Linoleic acid-BSA Chemical Sigma L9530 Shared during
communication with authors.
Insulin, transferrin,
sodium selenite supplement
Growth factor Roche (Sigma) 1074547 Shared during
communication with authors.
Dialyzed FCS Cell culture Sigma F0392 Shared during
communication with authors.
EGF; human Growth factor Sigma E9644 Shared during
communication with authors.
PDGF-BB, rat Growth factor R&D Systems 520-BB-050 Shared during
communication with authors.
Penicillin-Streptomycin; 100X Cell culture Sigma P4333 Original source not specified.
Leukemia inhibitory factor (LIF);
human; 10 mg/ml
Growth factor Sigma L5283 Shared during communication with authors.
Replaces LIF generated from CHO LIF720D cells.
Fibronectin; 0.1% in PBS Chemical Sigma F1141 Shared during
communication with authors.
Procedure
. All cell lines will be sent for STR profiling and mycoplasma testing.
. SK-N-MC cells are maintained in RPMI-1640 with 10% FBS.
. MPCs are maintained in DMEM:MCDB (60:40) supplemented with 100 mM ascorbic acid-2-
phosphate, 1 nM dexamethasone, 0.2 mg/ml linoleic acid-BSA, 5 mg/ml insulin, 5 mg/ml trans-
ferrin, 5 ng/ml sodium selenite, 2% dialyzed FCS, 10 ng/ml human EGF, 10 ng/ml rat PDGF-
BB, 1X penicillin/streptomycin, and 10 ng/ml LIF. Coat culture dishes for cells with fibronectin
(0.0001% in PBS) for 3 hr at 37˚C (or 4˚C overnight) before plating. Additional details available
at: https://osf.io/2vxnj/?view_only=7c9fb185e4c64ae78660cad92083aaa1
. All cells are kept at 37˚C and 5% CO2.
. Olaparib is stored as a 10 mM stock in DMSO at -80˚C. Each aliquot is subjected to no more
than 5 freeze-thaw cycles.
1. Determine seeding density of each cell line so cells will be in the growth phase at the end of
the assay (~70% confluency):
a. Plate 500 – 1.6x104EWS-FLI1 transformed MPCs, FUS-CHOP transformed MPCs, and SK-
N-MC cells in 96 well plates with 100 ml of appropriate medium in technical triplicate.
Seed three plates for measurements at 48, 72, and 96 hr after seeding. Incubate
overnight.
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b. 48 hr after seeding fix cells in 4% paraformaldehyde (PFA) for 30 min at 37˚C.
i. Stain cells with 1 mM Syto60 fluorescent nuclear dye, diluted in PBS, for 1 hr follow-
ing manufacturer’s instructions.
1. Wash out excess Syto60 prior to signal reading.
ii. Measure fluorescent signal intensity with a fluorescent plate reader.
c. 24 hr later (72 hr after seeding) fix and stain cells with Cyto60 as described above and
measure fluorescent signal intensity.
d. 24 hr later (96 hr after seeding) fix and stain cells with Cyto60 as described above and
measure fluorescent signal intensity.
i. Use seeding density for each cell line that results in sub-confluency (~70%) at the
end of the assay and where the signal is still in the linear range.
2. Seed cells at density determined in step 1 above in 96-well plates and let grow overnight.
a. Seed 21 wells per cell line.
i. Each cell line will be treated with 7 concentrations of drug in technical triplicate (see
Sampling section above).
b. Seed additional wells in technical triplicate per cell line for measurements at 24, 48, and
72 hr after treatment to test for proliferation of cells (no-treatment condition).
3. The next day, treat cells with a range of concentrations of olaparib.
a. No-treatment [additional]
b. Vehicle (DMSO at 0.1% v/v)
c. 0.39 mM olaparib
d. 0.78 mM olaparib
e. 1.56 mM olaparib
f. 3.13 mM olaparib
g. 6.25 mM olaparib
h. 12.5 mM olaparib
4. Incubate for 24, 48, or 72 hr.
a. Medium does not need to be changed during this period.
b. No-treatment wells are incubated for 24, 48, or 72 hr.
c. Olaparib or vehicle treated wells are incubated for 72 hr.
5. After 24, 48, or 72 hr fix cells in 4% PFA for 30 min at 37˚C.
6. Stain cells with 1 mM Syto60 fluorescent nuclear dye, diluted in PBS, for 1 hr following manu-
facturer’s instructions.
a. Wash out excess Syto60 prior to signal reading.
7. Measure fluorescent signal intensity with a fluorescent plate reader.
a. Excitation wavelength: 630 nm
b. Emission wavelength: 694 nm
8. Repeat steps 2–7 independently two additional times.
Deliverables
. Data to be collected:
 Raw data of fluorescent readout for all wells
 Graph of normalized readings for each drug concentration compared to vehicle only con-
trol (Compare to Figure 4E)
Confirmatory analysis plan
. Statistical Analysis of the Replication Data:
Note: At the time of analysis, we will perform the Shapiro-Wilk test and generate a quantile-
quantile plot to assess the normality of the data. We will also perform Levene’s test to assess
homoscedasticity. If the data appears skewed we will perform the appropriate transformation
in order to proceed with the proposed statistical analysis. If this is not possible we will perform
the planned comparisons using the equivalent non-parametric test.
 One way ANOVA on IC50 values of olaparib, determined by spline interpolation, of each
cell line with the following planned comparisons using Fisher’s LSD test:
& EWS-FLI1 transformed MPCs vs. FUS-CHOP transformed MPCs
& FUS-CHOP transformed MPCs vs. SK-N-MC cells
. Meta-analysis of original and replication attempt effect sizes:
 This replication attempt will perform the statistical analysis listed above, compute the
effect sizes, compare them against the reported effect size in the original paper and use a
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meta-analytic approach to combine the original and replication effects, which will be pre-
sented as a forest plot.
Known differences from the original study
. Commercially available LIF will be used in place of LIF generated from CHO LIF720D cells, as
suggested by the original authors.
. All known differences are listed in the materials and reagents section above with the originally
used item listed in the comments section. All differences have the same capabilities as the
original and are not expected to alter the experimental design.
Provisions for quality control
The cell lines used in this experiment will undergo STR profiling to confirm identity and will be sent
for mycoplasma testing to ensure there is no contamination. The DMSO concentration, although not
originally reported, will be kept at a low percentage to avoid toxicity. The seeding density of each
cell line will be empirically determined prior to conducting the replicates so cells will be still be in
the growth phase at the end of the assay. Measurements will be taken at 24, 48, and 72 hr after
seeding from cells not treated with drug to test for proliferation of cells during the assay. All data
obtained from the experiment will be made publicly available, either in the published manuscript or
as an open access dataset available on the OSF (https://osf.io/nbryi/).
Protocol 3: Olaparib sensitivity after depletion of EWS-FLI1 from A673
cells
This experiment assesses the sensitivity of PARP inhibitors to the presence of the EWS-FLI1 rearrange-
ment. EWS-FLI1 specific siRNA will be used to deplete the fusion mRNA from A673 cells, which harbor
the translocation endogenously, and cell viability after olaparib treatment will be assessed. This proto-
col replicates the experiment reported in Figure 4F and Supplemental Figure 20.
Sampling
. The experiment will be repeated three times for a minimum power of 80%.
 See Power calculations for details.
. The experiment has 2 cohorts:
 Cohort1: siControl transfected A673 cells
 Cohort 2: siEF1 transfected A673 cells
. Each cohort will be treated with the following conditions to assess cell viability in technical
triplicate:
 Untreated
 100 uM olaparib or DMSO equivalent
 33.33 uM olaparib or DMSO equivalent
 11.11 uM olaparib or DMSO equivalent
 3.704 uM olaparib or DMSO equivalent
 1.235 uM olaparib or DMSO equivalent
 0.412 uM olaparib or DMSO equivalent
 0.137 uM olaparib or DMSO equivalent
 0.046 uM olaparib or DMSO equivalent
 0.015 uM olaparib or DMSO equivalent
. Each cohort will be treated with the following conditions for qRT-PCR analysis:
 1.3 mM olaparib or DMSO equivalent
. Quantitative RT-PCR performed in technical triplicate for the following genes:
 EWS-FLI1
 RPLP0 (internal control)
Materials and reagents
Reagent Type Manufacturer Catalog # Comments
A673 cells Cell line ATCC CRL-1598 Source shared during
communication with authors.
Continued on next page
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Continued
Reagent Type Manufacturer Catalog # Comments
Olaparib Inhibitor Selleck Chemicals S1060 Source shared during
communication with authors.
DMSO Chemical Sigma D2650 Source shared during
communication with authors.
siEF1 Nucleic acid Qiagen Custom order 5’-GGCAGCAGAACCCUUCUUACG-3’
siCT control siRNA Nucleic acid Qiagen SI03650318 Catalog number shared during
communication with authors.
Cell Titer 96 Aqueous One
Solution Cell Proliferation Assay
Reporter assay Promega G3582
DMEM - High Glucose Cell culture GE-Healthcare E15-883 Shared during
communication with authors.
FBS Cell culture Valley Biomedical BS3032 Original source not specified.
O-MEM Cell culture Gibco 31985-062 Shared during
communication with authors.
96 well tissue culture test plates Labware TPP 92096 Source shared during
communication with authors.
Lipofectamine RNAiMAX Cell culture Life Technologies 13778-150 Shared during
communication with authors.
High-capacity cDNA reverse
transcription kit
Kit Applied Biosystems 4368814 Shared during
communication with authors.
NucleoSpin RNA II kit Kit Machery-Nagel 740955.50 Shared during
communication with authors.
Power SYBR Green PCR mastermix Kit Applied Biosystems 4367659 Shared during
communication with authors.
qPCR machine Equipment ABI/PRISM 7500 Shared during
communication with authors.
EWS-FLI1 primers Nucleic acid Synthesis left to the discretion of the
replicating lab and recorded later
Sequence shared during
communication with authors.
RPLP0 primers Nucleic acid Sequence shared during
communication with authors.
GloMax Multi+ Detection
System (spectrophotometer)
Equipment Promega 9311-011 Shared during communication with authors.
Replaces BMG FLUOstar OPTIMA microplate reader.
Procedure
Notes:
. All cell lines will be sent for STR profiling and mycoplasma testing.
. A673 cells are maintained in DMEM with 10% FBS.
. All cells are kept at 37˚C and 5% CO2.
. Olaparib is stored as a 10 mM stock in DMSO at -80˚C. Each aliquot is subjected to no more
than 5 freeze-thaw cycles.
. siRNA stocks kept at 20 mM; final siRNA concentration is 25 nM.
1. Seed cells for assays:
a. For cell viability assay, plate 5000 A673 cells per well in 64 ml medium without antibiotics
in a 96-well plate.
i. Seed enough cells for each condition to be performed in technical triplicate.
b. For qRT-PCR, plate 3x104 A673 cells per well of a 24 well plate in medium without
antibiotics.
i. This is a similar seeding density as the 96 well plate.
2. Immediately transfect cells with 25 nM siControl or siEF1 siRNAs using Lipofectamine RNAi-
MAX with the cells in suspension. The following directions prepare enough transfection mix-
ture for one 96-well plate. The amounts will be scaled accordingly to account for the plates
used for the qRT-PCR analysis.
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a. Mix 12.17 ml of 20 mM siRNA stock with 962.1 ml of OptiMEM.
b. Mix 18.26 ml of Lipfectamine RNAiMAX with 956 ml OptiMEM.
c. Gently mix the two solutions together and incubate for 12 min at room temperature.
d. Add 16 ml of transfection mixture per well to appropriate wells.
3. Immediately after siRNA transfection, treat cells with varying concentrations of olaparib or
vehicle (DMSO).
a. See Sampling section above for details; include untreated cells and cells treated with vehi-
cle only
b. Prepare a 500 mM stock of Olaparib by adding 30 ml of 10 mM stock to 570 ml of DMEM.
c. Prepare a stock of DMSO by adding 30 ml of DMSO to 570 ml of DMEM.
i. These will be used for the vehicle treated cells.
d. For cell viability assay, dilute olaparib and DMSO in DMEM by three-fold serial dilution as
outlined:
Experimental wells
Control
Olaparib
(mM) Background
No drug 100 33.33 11.11 3.704 1.235 0.412 0.137 0.046 0.015 No cells
DMSO (mL used in olaparib dilution)
1 0.333 0.111 0.037 0.012 0.004 0.001 5x10-4 2x10-4
Vehicle only wells
DMSO (mL/well, no olaparib)
1 0.333 0.111 0.037 0.012 0.004 0.001 5x10-4 2x10-4
i. Add 20 ml of each dilution to appropriate wells. Final volume per well is 100 ml.
e. For qRT-PCR, treat cells with 1.3 mM olaparib or equivalent volume of DMSO.
i. Dilute 500 mM stock of olaparib or stock of DMSO to create 6.5 mM (5X working
solution) in DMEM. Add to plate to achieve 1.3 mM olaparib or equivalent volume of
DMSO (0.013%).
4. Incubate cells for 72 hr.
a. Medium does not need to be changed during this time period.
5. Measure cell viability by using the Cell Titer 96 well aqueous one assay according to the manu-
facturer’s instructions.
a. Add 20 ml Cell Titer 96 Aqueous solution reagent per well containing 100 ml medium.
b. Incubate plate at 37˚C in humidified 5% CO2 for 4 hr.
c. Record absorbance at 490 nm using a BMG FLUOstar OPTIMA microplate reader.
i. Subtract average background (no cell) wells from each treated (olaparib or DMSO)
well.
ii. Normalize values to corresponding untreated (no drug or vehicle) wells for each
cohort.
iii. Determine IC50 value for each cohort using normalized olaparib values.
6. qRT-PCR to confirm knockdown of EWS-FLI1 expression:
a. Extract RNA with the NuceloSpin RNA II kit according to manufacturer’s instructions.
i. Record A260/A280 and A260/A230 ratios.
b. Synthesize cDNA using 1 mg of RNA and the High-capacity cDNA reverse transcription kit
according to the manufacturer’s instructions.
c. Perform qPCR using POWER SYBR Green PCR mastermix according to the manufacturer’s
instructions in technical triplicate.
i. Primers:
1. EWS-FLI1(forward):
a. 5’-GCCAAGCTCCAAGTCAATATAGC-3’
2. EWS-FLI1(reverse):
a. 5’-GAGGCCAGAATTCATGTTATTGC-3’
3. RPLP0(forward): Internal Control
a. 5’-GAAACTCTGCATTCTCGCTTC-3’
4. RPLP0(reverse): Internal Control
a. 5’-GGTGTAATCCGTCTCCACAG-3’
ii. Reaction conditions run on an ABI PRISM 7500.
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1. 95˚C for 10 min
2. 40 cycles of:
a. 95˚C for 15 s
b. 60˚C for 1 min
3. Dissociation curve
iii. Analyze with 7500 SDS software or equivalent.
d. Calculate relative EWS-FLI1 expression for each sample using RPLP0 as internal standard.
7. Repeat independently two additional times.
Deliverables
. Data to be collected:
 Raw absorbance values for all wells.
 Graph of absorbance corrected values for all concentrations of olaparib or DMSO normal-
ized to untreated controls (as seen in Figure 4F).
 IC50 values for each cohort using normalized olaparib values.
 Raw and normalized qRT-PCR data (as seen in Supplemental Figure 20).
Confirmatory analysis plan
. Statistical Analysis of the Replication Data:
Note: At the time of analysis, we will perform the Shapiro-Wilk test and generate a quantile-
quantile plot to assess the normality of the data. We will also perform Levene’s test to assess
homoscedasticity. If the data appears skewed we will perform the appropriate transformation
in order to proceed with the proposed statistical analysis. If this is not possible we will perform
the planned comparisons using the equivalent non-parametric test.
 o Viability assay:
& Unpaired two-tailed t-test of olaparib IC50 values of siControl transfected cells com-
pared to siEF1 transfected cells.
 qRT-PCR:
& Two-way ANOVA of siControl and siEF1 transfected cells treated with or without
olaparib with the following planned comparisons using the Bonferroni correction:
. siControl transfected cells treated with DMSO compared to siEF1 transfected
cells treated with DMSO.
. siControl transfected cells treated with olaparib compared to siEF1 transfected
cells treated with olaparib.
. Meta-analysis of original and replication attempt effect sizes:
 This replication attempt will perform the statistical analysis listed above, compute the
effect sizes, compare them against the reported effect size in the original paper and use a
meta-analytic approach to combine the original and replication effects, which will be pre-
sented as a forest plot.
Known differences from the original study
. All known differences are listed in the materials and reagents section above with the originally
used item listed in the comments section. All differences have the same capabilities as the
original and are not expected to alter the experimental design.
Provisions for quality control
The cell line used in this experiment will undergo STR profiling to confirm identity and will be sent
for mycoplasma testing to ensure there is no contamination. The sample purity (A260/280 ratio) of the
isolated RNA from each sample will be reported. All data obtained from the experiment will be
made publicly available, either in the published manuscript or as an open access dataset available
on the OSF (https://osf.io/nbryi/).
Power calculations
For additional details on power calculations, please see analysis scripts and associated files on the
Open Science Framework:
https://osf.io/j9bnk/
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Protocol 1
Summary of original data estimated from graph reported in Figure 4C
Cell type Cell line Effective concentration (mM)
Ewing’s
sarcoma
ES1 1
ES6 1
ES7 0.32
ES8 1
MHH-ES-1 0.32
Osteosarcoma CAL-72 10
HOS 1
HuO-3N1 3.2
MG-63 3.2
NY 3.2
SAOS-2 3.2
SJSA-1 10
U-2-OS 10
BRCA2-deficient DoTc2-4510 0.32
Test family
& Wilcoxon-Mann-Whitney test (ordinal data): alpha error = 0.05
Power calculations
. Power calculations were performed with R software, version 3.2.2 (R Development Core
Team, 2015).
Group 1 Group 2
Effect size
(Cliff’s delta) A priori power
Group 1
sample size
Group 2
sample size
Ewing’s sarcoma Osteosarcoma 0.92500 81.8% 5 7
Protocol 2
Summary of original data reported in Figure 4E (shared by authors)
Cell line Concentration of olaparib (mM) Mean SD N
EWS-FLI1 transformed MPCs 0 1 0.06 3
0.39 0.59 0.05 3
0.78 0.53 0.09 3
1.56 0.44 0.05 3
3.13 0.34 0.05 3
6.25 0.24 0.04 3
12.5 0.22 0.04 3
Continued on next page
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Continued
Cell line Concentration of olaparib (mM) Mean SD N
FUS-CHOP transformed MPCs 0 1 0.09 3
0.39 1.06 0.01 3
0.78 1.03 0.06 3
1.56 1.11 0.08 3
3.13 0.98 0.09 3
6.25 0.59 0.07 3
12.5 0.45 0.04 3
SK-N-MC 0 1 0.04 3
0.39 0.66 0.04 3
0.78 0.66 0.09 3
1.56 0.50 0.01 3
3.13 0.40 0.04 3
6.25 0.30 0.05 3
12.5 0.25 0.03 3
IC50 values of olaparib, determined by spline interpolation.
Calculations performed with R software, version 3.2.2 (R Development Core Team, 2015).
Cell line Mean SD N
EWS-FLI1 transformed MPCs 1.0502 0.5363 3
FUS-CHOP transformed MPCs 7.7963 1.3024 3
SK-N-MC 1.5449 0.0505 3
Test family
& Two-tailed t test, Wilcoxon-Mann-Whitney test, Fisher’s LSD: alpha error = 0.05
Power Calculations performed with G*Power software, version 3.1.7 (Faul et al., 2007).
Group 1 Group 2 Effect size d A priori power
Group 1
sample size
Group 2
sample size
EWS-FLI1
transformed MPCs
FUS-CHOP transformed MPCs 6.77343 83.8%1 21 21
SK-N-MC FUS-CHOP transformed MPCs 6.78283 83.8%1 21 21
1 3 samples per group will be used as a minimum making the power 99.9%.
Test family
& Due to the large difference in variance, these parametric tests are only used for comparison
purposes. The sample size is based on the non-parametric tests listed above.
& ANOVA: Fixed effects, omnibus, one-way: alpha error = 0.05.
Power Calculations performed with G*Power software, version 3.1.7 (Faul et al., 2007).
ANOVA F test statistic and partial h2 performed with R software, version 3.2.2 (R Development
Core Team, 2015).
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Groups
F test
statistic Partial h2 Effect size f
A priori
power Total sample size
EWS-FLI1 transformed MPCs,
FUS-CHOP transformed MPCs,
and SK-N-MC
F(2,6) = 64.06 0.95526 4.62097 99.9% 61 (3 groups)
1 9 total samples (3 per group) will be used as a minimum.
Test family
& Due to the large difference in variance, these parametric tests are only used for comparison
purposes. The sample size is based on the non-parametric tests listed above.
& Two-tailed t test, difference between two independent means, Fisher’s LSD: alpha error =
0.05
Power Calculations performed with G*Power software, version 3.1.7 (Faul et al., 2007).
Group 1 Group 2 Effect size d A priori power Group 1 sample size Group 2 sample size
EWS-FLI1 transformed MPCs FUS-CHOP transformed MPCs 6.77343 89.9%1 21 21
SK-N-MC FUS-CHOP transformed MPCs 6.78283 89.9%1 21 21
1 3 samples per group will be used as a minimum making the power 99.9%.
Protocol 3
Viability assay
Summary of original data reported in Figure 4F (shared by authors)
siRNA
Concentration of olaparib (mM)
or volume of DMSO (ml) Mean SD N
siControl
(DMSO treatment)
0 ml 97.3360 0.95391 3
2x10-4 ml 102.203 3.70013 3
5x10-4 ml 100.088 0.90226 3
0.001 ml 94.8628 1.30022 3
0.004 ml 100.095 3.84743 3
0.012 ml 107.634 1.05370 3
0.037 ml 110.378 4.41561 3
0.111 ml 111.467 0.68191 3
0.333 ml 104.501 1.98400 3
1.000 ml 107.905 1.61184 3
siControl
(olaparib treatment)
0 mM 102.664 2.82201 3
0.0152 mM 95.9921 1.18048 3
0.046 mM 83.1889 2.80989 3
0.1371 mM 81.8370 2.93976 3
0.411 mM 72.4056 3.10030 3
1.234 mM 54.9026 2.74523 3
3.70 mM 16.0636 3.50915 3
11.11 mM 1.28032 0.61000 3
33.33 mM -1.45527 1.64101 3
100 mM 2.28231 2.39427 3
Continued on next page
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Continued
siRNA
Concentration of olaparib (mM)
or volume of DMSO (ml) Mean SD N
siEF1
(DMSO treatment)
0 ml 99.0971 1.13436 3
2x10-4 ml 99.6397 1.21598 3
5x10-4 ml 95.3622 0.45115 3
0.001 ml 90.4599 4.31934 3
0.004 ml 94.3179 0.86896 3
0.012 ml 95.1752 2.35064 3
0.037 ml 96.3837 1.39419 3
0.111 ml 96.7576 1.13467 3
0.333 ml 95.4762 1.38497 3
1.000 ml 97.2365 1.24839 3
siEF1
(olaparib treatment)
0 mM 100.903 3.87004 3
0.0152 mM 97.9023 4.77067 3
0.046 mM 95.4853 5.47687 3
0.1371 mM 93.9713 2.33965 3
0.411 mM 89.4430 4.97093 3
1.234 mM 76.6332 2.436545 3
3.70 mM 45.0396 1.67473 3
11.11 mM 18.7815 1.78436 3
33.33 mM 11.7541 3.75220 3
100 mM 11.7997 2.22773 3
IC50 values of olaparib, determined by four-parameter log-logistic function.
Calculations performed with R software, version 3.2.2 (R Development Core Team, 2015).
Cell line Mean SD N
siControl 1.35191 0.0684 3
siEF1 2.74561 0.1715 3
Test family
& Two-tailed t test, Wilcoxon-Mann-Whitney test: alpha error = 0.05
Power Calculations performed with G*Power software, version 3.1.7 (Faul et al., 2007).
Group 1 Group 2 Effect size d A priori power Group 1 sample size Group 2 sample size
siControl siEF1 10.67494 98.7%1 21 21
1 3 samples per group will be used as a minimum making the power 99.9%.
Test family
& Due to the large difference in variance, these parametric tests are only used for comparison
purposes. The sample size is based on the non-parametric tests listed above.
& Two-tailed t test, difference between two independent means: alpha error = 0.05
Power Calculations performed with G*Power software, version 3.1.7 (Faul et al., 2007).
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Group 1 Group 2 Effect size d A priori power Group 1 sample size Group 2 sample size
siControl siEF1 10.67494 99.6%1 21 21
1 3 samples per group will be used as a minimum making the power 99.9%.
qRT-PCR
Summary of original data estimated from graph reported in Supplemental Figure 20.
Treatment siRNA Mean SD N
DMSO siControl 100 22.9 3
siEF1 4.75 0.838 3
1.3 mM olaparib siControl 90.5 14.5 3
siEF1 7.26 0.838 3
Test family
& Two-tailed t test, Wilcoxon-Mann-Whitney test, Bonferroni’s correction: alpha error = 0.025
Power Calculations performed with G*Power software, version 3.1.7 (Faul et al., 2007).
Group 1 Group 2 Effect size d A priori power Group 1 sample size Group 2 sample size
siControl cells treated with DMSO siEF1 cells treated with DMSO 5.87713 98.3% 3 3
siControl cells treated with olaparib siEF1 cells treated with olaparib 8.09108 99.9% 3 3
Test family
& Due to the large difference in variance, these parametric tests are only used for comparison
purposes. The sample size is based on the non-parametric tests listed above.
& ANOVA: Fixed effects, special, main effects and interactions: alpha error = 0.05.
Power Calculations performed with G*Power software, version 3.1.7 (Faul et al., 2007).
ANOVA F test statistic and partial h2performed with R software, version 3.2.2 (R Development
Core Team, 2015).
Groups F test statistic Partial h2 Effect size f A priori power Total sample size
A673 cells transfected with
siControl or siEF1 and treated
with DMSO or olaparib
F(1,8) = 129.85 (main effect: siRNA) 0.94196 4.02877 99.2%1 61
(4 groups)
1 12 samples (3 per group) will be used based on the planned comparisons making the power 99.9%.
Test family
& Due to the large difference in variance, these parametric tests are only used for comparison
purposes. The sample size is based on the non-parametric tests listed above.
& 2 tailed t test, difference between two independent means, Bonferroni’s correction: alpha
error = 0.025
Power Calculations performed with G*Power software, version 3.1.7 (Faul et al., 2007).
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Group 1 Group 2 Effect size d A priori power Group 1 sample size Group 2 sample size
siControl cells
treated with DMSO
siEF1 cells treated
with DMSO
5.87713 99.1% 3 3
siControl cells
treated with olaparib
siEF1 cells treated
with olaparib
8.09108 80.6%1 21 21
1 3 samples per group will be used based on the other comparions making the power 99.9%.
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